Trials / Completed
CompletedNCT02448784
Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).
Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 591 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To investigate long term safety (especially about Parkinsonism) and efficacy of donepezil hydrochloride in clinical practice as well as its proper use information in participants with DLB.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Donepezil Hydrochloride | Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant. |
Timeline
- Start date
- 2015-04-20
- Primary completion
- 2017-03-30
- Completion
- 2017-03-30
- First posted
- 2015-05-19
- Last updated
- 2018-07-11
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02448784. Inclusion in this directory is not an endorsement.